Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

ABSTRACT:

Background

Idiopathic pulmonary fibrosis represents a lethal form of progressive fibrotic lung disorder with gradually increasing incidence worldwide. Despite intense research efforts its pathogenesis is still elusive and controversial reflecting in the current disappointing status regarding its treatment.

Patients and methods

We report the first protocol proposal of a prospective, unicentric, non-randomized, phase Ib clinical trial to study the safety and tolerability of the adipose-derived stem cells (ADSCs) stromal vascular fraction (SVF) as a therapeutic agent in IPF. After careful patient selection based on functional criteria (forced vital capacity-FVC > 50%, diffuse lung capacity for carbon monoxide-DLCO > 35% of the predicted values) all eligible subjects will be sub

SUBMITTER: Tzouvelekis A 

PROVIDER: S-EPMC3213183 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature